ESCC

NIAID Data Ecosystem2026-05-02 收录

食管癌免疫治疗

临床试验生存分析

数据链接：

https://www.ncbi.nlm.nih.gov/sra/SRP415827 数据链接链接失效反馈

官方服务：

资源简介：

Neoadjuvant anti-PD-L1 checkpoint blockade in locally advanced resectable esophageal squamous cell carcinoma: survival and immunologic analyses of NATION-1907 trial

创建时间：

2025-01-01

CALGB 9344 (validation set) observed and predicted 15 year survival estimates.

乳腺癌预后

临床试验生存分析

CALGB 9344 (validation set) observed and predicted 15 year survival estimates.

NIAID Data Ecosystem50

Supplementary Material for: Clinical Impact of Early Tumour Shrinkage in Metastatic or Unresectable Oesophageal Cancer Treated with Pembrolizumab plus Chemotherapy

食管癌免疫治疗

癌症疗效预测

Introduction: Metastatic or unresectable locally advanced oesophageal cancer remains a disease with high mortality. More recently, pembrolizumab plus chemotherapy has been indicated as the first-line

Figshare2023-12-05 更新20

Data Sheet 1_The efficacy and safety of PD-1 inhibitors combined with chemotherapy treatment for advanced esophageal cancer: a network meta-analysis.pdf

食管癌免疫治疗

PD-1抑制剂疗效评估

ObjectiveThis study systematically evaluated the efficacy of programmed death 1 (PD-1) inhibitors combined with chemotherapy for advanced esophageal cancer (EC). MethodsPubMed, Embase, Web of Science,

NIAID Data Ecosystem10

LUD2015-005 Publication Code Release (Fuchs et al. 2026)

癌症生物标志物

食管癌免疫治疗

Release of code and supplementary data to recreate bioinformatics analyses and figure generation for the following publication from the LUD2015-005 Project Team: "Expression levels of CFISH (CXCL8, FC

Zenodo2026-05-09 更新30

Cetuximab + Irinotecano vs chemoterapia standard nel carcinoma colo-rettale avanzato pretrattato non resecabile esprimente EGFR

结直肠癌靶向治疗

临床试验生存分析

Primary objectives: Sopravvivenza globale

NIAID Data Ecosystem20